In this review:
Chemotherapy dose intensification improves outcomes
Adjuvant trastuzumab: no benefit in weakly HER2+ disease
No benefit in continuing anastrozole beyond 7 years
1 year vs 9 weeks adjuvant trastuzumab in HER2+ disease
Weekly paclitaxel vs nab-paclitaxel in chemotherapy-naïve metastatic disease
Acupuncture relieves AI-induced joint symptoms
A novel tool predicts late distant relapse in ER+ disease
Association between CTC status and disease recurrence
EndoPredict predicts response to neoadjuvant therapy?
Talazoparib in advanced disease and a germline BRCA mutation
Please login below to download this issue (PDF)